Policy & Regulation

WACKER posted a €805 million net loss in 2025, while its PACE savings plan is now central to any recovery in 2026.

Key 2026 pharmaceutical regulatory updates across UAE, Saudi Arabia, GCC, Egypt and global agencies, with practical compliance insights for pharma companies.

• UAE
• MENA region
• Drugs
• Regulation
• pharmaceutical policy

Over the past 72 hours, the security situation in key Middle Eastern maritime corridors — the Strait of Hormuz and the Red Sea — has deteriorated again.

FDA loosens “no artificial colors” claims while green-lighting new natural dyes—sparking a fierce debate over what “clean” really means.

FDA reopens BHA safety review, signaling a global shift toward tighter oversight of legacy food additives.

Key ECHA regulatory updates affecting REACH, CLP, and Drinking Water compliance. Practical guidance for EU chemical operators.

• Echa
• REACH
• CLP

Gone are the days when “boosts plant vitality” or “enhances natural defenses” could carry a bio-stimulant to market in Europe. Under the ironclad framework of the EU Fertilising Products Regulation (FPR) (EU) 2019/1009, the era of concept-driven marketing

Ministry of Health, Labour and Welfare (MHLW) has unveiled a nuanced revision to its food additive standards—one that simultaneously restricts one ingredient while expanding another’s use in everyday beverages.

U.S. Food and Drug Administration (FDA) took an action that offered palpable relief to the global weight-loss drug market: it instructed pharmaceutical companies to remove warnings about “suicidal ideation and suicidal behavior” from the labels of certain

On December 23, 2025, Beijing Oriental Yuhong Waterproof Technology Co., Ltd.issued a startling announcement: its wholly owned U.S. subsidiary, OYH Construction Materials LLC, had likely fallen victim to a sophisticated telecom fraud scheme.

The global pesticide market has entered a period of stagnation and downward pressure, with weak demand and oversupply pushing most active ingredients into a prolonged correction phase.

In a landmark regulatory first, the U.S. FDA has qualified its first artificial-intelligence tool designed to accelerate liver-disease drug development, validating AI as an official decision-support instrument in pharmaceutical research.

The U.S. Food and Drug Administration has launched a fresh safety scrutiny of newly approved RSV therapies for infants, signaling heightened regulatory caution as real-world usage expands.

Recently, our ECHEMI platform has received feedback from suppliers that some users have used the ECHEMI inquiry and quotation notification reply email (as shown in the case below) to guide suppliers to click on attached link for account login.

The ECHEMI platform has always kept a close eye on real-time global exhibition trends in various chemical fields, including pharmaceuticals, coatings, food, and more, and maintains strategic alliance cooperation with global exhibition companies.

In a stark warning to Chinese food exporters, the U.S. Food and Drug Administration (FDA) issued multiple automatic detention alerts in early November 2025, targeting firms from Ningxia to Fujian for serious compliance failures.

U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur, a long-time oncology expert, as the director of its Center for Drug Evaluation and Research (CDER).

Health Canada’s Directorate has issued a non-compliance notice to Dr. Reddy’s Laboratories regarding its generic semaglutide for weight loss, raising questions over the company’s regulatory pathway in North America.